Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Insmed Inc shares valued at $233,308 were purchased by Wise John Drayton on May 28 ’25. At $68.00 per share, Wise John Drayton acquired 3,431 shares.
Also, Desjardins Clarissa purchased 1,895 shares, netting a total of over 126,719 in proceeds. Following the buying of shares at $66.87 each, the insider now holds 1,895 shares.
Before that, Desjardins Clarissa had added 1,130 shares to its account. In a trade valued at $74,976, the Director bought Insmed Inc shares for $66.35 each. Upon closing the transaction, the insider’s holdings increased to 1,130 shares, worth approximately $0.2 million.
As published in their initiating research note from Jefferies on May 13, 2025, Insmed Inc [INSM] has been a Buy and the price target has been revised to $105. Analysts at RBC Capital Mkts started covering the stock with ‘”an Outperform”‘ outlook in a report released in late February. As of April 23, 2024, Truist has initiated its “Buy” rating for INSM. Earlier on February 15, 2024, Wolfe Research initiated its rating. Their recommendation was “an Outperform” for INSM stock.
Analyzing INSM Stock Performance
During the last five days, there has been a drop of approximately -3.14%. Over the course of the year, Insmed Inc shares have dropped approximately -3.88%. Shares of the company reached a 52-week high of $84.91 on 02/21/25 and a 52-week low of $60.40 on 04/09/25.
Support And Resistance Levels for Insmed Inc (INSM)
According to the 24-hour chart, there is a support level at 65.54, which, if violated, would cause prices to drop to 64.71. In the upper region, resistance lies at 67.73. The next price resistance is at 69.09. RSI (Relative Strength Index) is 43.58 on the 14-day chart, showing neutral technical sentiment.
